Sign inJoin waitlistJoin the waitlist

Mohammad Atiq

Assistant Professor of Medicine · University of Chicago Medical Center

Credentials: · · · · · ·

History

University of Chicago Medical Center
Present
University of Chicago Medical Center
Present

Baylor College of Medicine
2022–2024
Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2019–2022
National Institutes of Health
Internal Medicine
University of Arkansas for Medical Sciences
2014–2017
Univ of Arkansas Coll of Med
2010–2014

Research

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
Clinical Cancer Research · 2019 · 115 citations
Breast Cancer Immunotherapy: An Update
Review · Breast Cancer · 2018 · 57 citations
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Molecular Oncology · 2020 · 30 citations

NP
Nabeela Patail
4 papers · 4 as a fellow
PK
Philip Kantoff
4 papers
OA
Osman Atiq
3 papers · 1 as a resident
Saad Atiq
3 papers · 1 as a resident
Fatima Karzai
2 papers
Konrad Stopsack
2 papers
Omar Atiq
2 papers
Ravi Madan
2 papers
Wassim Abida
2 papers
AA
Ahmed Alwbari
1 paper
BJ
Blake Jacks
1 paper · 1 as a resident
CB
Connor Bell
1 paper

Clinical trials

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Site PI · Recruiting · Phase 1, Phase 2
Pathos AI, Inc.
2025–2029
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2031